---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-003490"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:33:02.282734+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galecto appoints Sherwin Sattarzadeh as COO; issues warrant to Paramora

## Summary
- Sherwin Sattarzadeh appointed COO effective Jan 5, 2026; base salary $540,000, target bonus 40%.
- Initial equity grant includes 190,376 RSUs and options for 444,209 shares vesting over four years.
- Issued warrant to Paramora for 628,302 shares at $23.01 per share under Paragon Option Agreement.
- Severance provisions: 12 months' salary (18 months if within Change in Control Period) plus accelerated vesting.

## SEC filing metadata
- accession: 0001193125-26-003490
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000119312526003490/0001193125-26-003490-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000119312526003490/glto-20251231.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-003490
- JSON: https://secwatch.observer/filing/0001193125-26-003490.json
- Plain text: https://secwatch.observer/filing/0001193125-26-003490.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.